Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
government agreed to spend $1.2 billion to purchase 1.7 million doses of Molnupiravir, a Merck product, if it were to be approved by regulators to treat COVID-19. In October 2021, the company said that the drug reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of COVID-19 and that it would seek Emergency Use Authorization for the drug. In July 2021, Robert M. Davis became CEO, succeeding Kenneth Frazier, who became executive chairman. In July 2021, Merck completed the corporate spin-off of Organon & Co. In September 2021, Merck announced it would acquire Acceleron Pharma for $11.5 billion, gaining control over Sotatercept, used in the treatment of pulmonary hypertension, and luspatercept-aamt. In September 2022, the company announced it would acquire Vence, a livestock management company for an undisclosed sum, incorporating it within Merck Animal Health. In December 2022, the company announced a licensing deal with Kelun-Biotech of China whereby it would expand its early cancer pipeline with a set of antibody-drug conjugates; this follows an earlier agreement between the two companies to co-develop such drugs. In April 2023, Merck announced it would acquire Prometheus Biosciences Inc for $10.8 billion. In December 2023, Merck announced it had partnered with Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for immunotherapies.
=== Physiological causes === Physiological (i.e., non-pathological) causes that can increase prolactin levels include: ovulation, pregnancy, breastfeeding, chest wall injury, stress, stress-associated REM sleep, and exercise. During pregnancy, prolactin increases can range up to 600 ng/mL, depending on estrogen and progesterone concentrations. After delivery, progesterone concentrations decrease, and prolactin levels drop. Only during nipple stimulation will prolactin levels rise, allowing for milk production. At 6 weeks post-birth (postpartum), estradiol concentrations decrease, and prolactin concentrations return to normal even during breastfeeding. Fluctuations in prolactin levels during menstrual cycles and menopause are inconclusive. Stress-related factors include physical exercise, hypoglycemia, myocardial infarction, and surgery. While aerobic and anaerobic activity increases prolactin, anaerobic activity has a greater effect. Coitus can also contribute to an increased prolactin release. Prolactin serum concentrations increase during nocturnal sleep, and increase transiently during daytime naps. After waking, prolactin levels return to daytime levels within 60–90 minutes.
=== Evolutionary rate === For sequence evolution, dN/dS analysis studies often indicate that de novo genes evolve at a higher rate compared to other genes. For expression evolution and structural evolution, quantitative studies across different evolutionary ages or phylostratigraphic branches are very few.
During the show's ninth season, which has subsequently been entirely retconned out of the series continuity, Bev comes out as a lesbian (according to one of Roseanne's fictional twists on her family, along with winning the lottery). In the finale, Roseanne states that it is her sister, Jackie, not Bev, who is a lesbian. This has also been retconned out of the series continuity. From what is known of Bev's childhood and marriage, her life was emotionally difficult, plagued with instability and neglect. Her unrestrained mother Mary put her personal freedom ahead of her children. As a result of her promiscuity, Mary is uncertain about who Bev's father was. As a young woman, Bev found herself pregnant out of wedlock, as her mother had been. Unlike her mother, Bev married her baby's father, Al Harris. Their marriage lasted several decades, but Al treated their two daughters harshly and cheated on Bev, having a secret mistress for twenty years. Disappointed in her life, Bev grew bitter in her old age, making her critical of others. Bev returned in season 10 of Rosanne, and in the subsequent follow-up series The Conners. In season 10 of Roseanne, Bev was kicked out of her retirement community for sleeping with others and spreading STIs; Jackie and Roseanne alternated keeping care of her at their respective homes.
=== Brand names === Cyclofenil has been marketed under a variety of brand names including Ciclifen, Fertodur, Gyneuro, Klofenil, Menoferil, Menopax, Neoclym, Oginex, Ondonid, Ondogyne, Rehibin, Sexadieno, Sexovar, and Sexovid.
Sources: en.wikipedia.org
Laser-based ambient ionization is a two-step process in which a pulsed laser is used to desorb or ablate material from a sample and the plume of material interacts with an electrospray or plasma to create ions. Lasers with ultraviolet and infrared wavelengths and nanosecond to femtosecond pulse widths have been used. Although atmospheric pressure MALDI is performed under ambient conditions, it is not generally considered to be an ambient mass spectrometry technique. Laser ablation was first coupled with mass spectrometry in the 1980s for the analysis of metals using laser ablation inductively coupled plasma mass spectrometry (LA-ICPMS). The laser ablates the sample material that is introduced into an ICP to create atomic ions.
In December 2010, 148 states supported a United Nations' General Assembly resolution calling for the states that use depleted uranium weapons in conflict to reveal where the weapons have been fired when asked to do so by the country upon whose territory they have been used. In April 2011, the Congress of Costa Rica passed a law prohibiting uranium weapons in its territories, becoming the second country in the world to do so. In December 2012, 155 states supported a United Nations' General Assembly resolution that recalled that, because of the ongoing uncertainties over the long-term environmental impacts of depleted uranium identified by the United Nations Environment Programme, states should adopt a precautionary approach to its use. In December 2014, 150 states supported a United Nations' General Assembly resolution encouraging states to provide assistance to states affected by the use of depleted uranium weapons, in particular in identifying and managing contaminated sites and material. In contrast to the previous biennial resolutions, Germany moved to an abstention from supporting to the resolutions. Prior to the vote, in a report to the United Nations Secretary General requested by 2012's resolution published in June 2014, Iraq had called for a global treaty ban on depleted uranium weapons.
== Hfe knockout mice == It is possible to delete part or all of a gene of interest in mice (or other experimental animals), as a means of studying the function of the gene and its protein. Such mice are called "knockouts" with respect to the deleted gene. Hfe is the mouse equivalent of the human hemochromatosis gene HFE. The protein encoded by HFE is Hfe. Mice homozygous (two abnormal gene copies) for a targeted knockout of all six transcribed Hfe exons are designated Hfe−/−. Iron-related traits of Hfe−/− mice, including increased iron absorption and hepatic iron loading, are inherited in an autosomal recessive pattern. Thus, the Hfe−/− mouse model simulates important genetic and physiological abnormalities of HFE hemochromatosis. Other knockout mice were created to delete the second and third HFE exons (corresponding to α1 and α2 domains of Hfe). Mice homozygous for this deletion also had increased duodenal iron absorption, elevated plasma iron and transferrin saturation levels, and iron overload, mainly in hepatocytes. Mice have also been created that are homozygous for a missense mutation in Hfe (C282Y). These mice correspond to humans with hemochromatosis who are homozygous for HFE C282Y. These mice develop iron loading that is less severe than that of Hfe−/− mice.
In addition to these shared features, comparative studies have identified metabolic and immunoregulatory traits that distinguish S. boulardii from many other S. cerevisiae strains and may contribute to its probiotic activity. These include elevated production of acetate and succinate under aerobic conditions, enhanced anti-inflammatory effects in cell-based models, and selective activation of the aryl hydrocarbon receptor (AhR), a key regulator of intestinal immune homeostasis. S. boulardii also encodes additional copies of flocculin genes, which may promote interactions with bacterial pathogens and reduce their adherence to the intestinal mucus layer. S. boulardii produces high amounts of the short-chain fatty acid acetic acid (acetate). This results in S. boulardii increasing acidity and having strong antibacterial properties. It also shows anti-inflammatory effects and can increase beneficial gut bacteria such as Akkermansiaceae and Bifidobacteriaceae via symbiotic mechanisms in preclinical research. The yeast has also been found to reverse antibiotic-induced gut dysbiosis in rodents, including restoring beneficial bacteria such as Lactobacillus, Bifidobacterium, Firmicutes, and Clostridium. This was associated with reduced neuroinflammation and related behavioral changes.
Sources: en.wikipedia.org
Cachexia ( ) is a syndrome that occurs in people with certain illnesses, causing muscle loss that cannot be fully reversed with improved nutrition. It most commonly occurs in cases of cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS. These conditions change how the body handles inflammation, metabolism, and brain signaling. This can lead to muscle loss and other harmful changes to body composition over time. Unlike weight loss from inadequate caloric intake, cachexia mainly causes muscle loss and can happen with or without fat loss. Diagnosis of cachexia is difficult because there are no clear guidelines, and its occurrence varies from one affected person to the next. Like malnutrition, cachexia can lead to worse health outcomes and lower quality of life. The prognosis of patients with cachexia varies depending on the type and severity of the underlying illness, but is typically poor, especially with patients in late stages of disease. Cachexia can improve significantly with effective treatment of the underlying illness, but symptomatic treatment approaches such as nutritional therapy and exercise typically do not result in reversal of the syndrome, and have very limited benefit in advanced cases of cachexia.
=== Producer/Engineer === Jawbreaker - "Chesterfield King" EP (Communion/Tupelo, 1991) Jawbreaker - Bivouac (Communion/Tupelo, 1991) Warlock Pinchers - Circusized Peanuts (Boner Records, 1991) Blister - Glitches (1992) (Executive Producer) Tumor Circus - Tumor Circus (Alternative Tentacles, 1991) Jello Biafra - I Blow Minds for a Living (Alternative Tentacles, 1991)
At MIT, David Richardson was pursuing his doctorate in Al Cotton's lab using X-ray crystallography to study the structure of staphylococcal nuclease. Jane Richardson learned the necessary technical skills and scientific background in biochemistry and biophysics through work at the lab as she worked alongside her husband, whom she still works with today. Richardson later began drawing her eponymous diagrams as a method of interpreting the structures of protein molecules. Over the course of her career, Richardson has been recognized by many prestigious institutions of the scientific community. In July 1985 she was awarded a MacArthur Fellowship for her work in biochemistry. She was elected to the National Academy of Sciences and the American Academy of Arts and Sciences in 1991 and to the Institute of Medicine in 2006. As part of her role in the National Academy of Sciences, Richardson serves on panels that advise the White House and the Pentagon regarding nationally important scientific matters (e.g.,). For the 2012-2013 year, Richardson was elected president of the Biophysical Society for the 2012-2013 year, and she became a fellow of the American Crystallographic Association in 2012. Richardson is currently a James B. Duke Professor of Biochemistry at Duke University. The Richardsons continue to jointly head a research group at Duke University. Richardson is a contributor to Wikipedia, where she is a prominent member of WikiProject Biophysics.
Theraflu (made by Novartis) — previously contained pseudoephedrine, now contains phenylephrine Trima — contains 60 mg pseudoephedrine hydrochloride Tylol Hot (made by NOBEL İLAÇ SANAYİİ VE TİCARET A.Ş., Turkey) — a packet of 20 g contains 60 mg pseudoephedrine hydrochloride, 500 mg paracetamol and 4 mg chlorpheniramine maleate Unifed (made by United Pharmaceutical Manufacturer, Jordan) — contains pseudoephedrine hydrochloride (also triprolidine and guaifenesin). Zyrtec-D 12 Hour (made by McNeil Consumer Healthcare, a Kenvue company) — contains 120 mg pseudoephedrine hydrochloride (also 5 mg of cetirizine). Zephrex-D (made by Westport Pharmaceuticals) – a special meth-resistant form of pseudoephedrine that becomes gooey when heated.
== Reception == Half-Life 2: Deathmatch was well-received upon its release, with reviewers praising its inclusion of the gravity gun. GameSpot lauded the game for the Source engine's "impressive use of physics" and the available selection of maps. IGN paid similar compliments to the title, also speaking highly of the "fast play style that [Half-Life 2: Deathmatch] produces." Multiple reviews stated that the game suffered from large amount of lag upon release, but GameSpy noted that this was remedied soon after as more servers came online.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。